Calvin Yeang (United States of America)
UCSD CardiologyAuthor Of 1 Presentation
O011 - Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements (ID 310)
Abstract
Background and Aims
Current methods for determining “LDL-C” in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. Prior studies suggested Lp(a) mass contains ~30% cholesterol. A high-throughput, sensitive and rapid method to quantitate Lp(a)-C and improve the accuracy of “LDL-C” was developed.
Methods
Lp(a) was isolated on magnetic beads linked to monoclonal antibody LPA4 recognizing apolipoprotein(a) and the cholesterol content measured with standard techniques. This method does not detect cholesterol in plasma samples lacking Lp(a) and is linear up to 747 nM Lp(a). LDL-Ccorr was determined as LDL-C - Lp(a)-C.
Results
Lp(a)-C and LDL-Ccorr were determined in 29 participants from a completed clinical trial of Lp(a) lowering with an antisense oligonucleotide. Baseline Lp(a) ranged from 9.0-822.8 nM, Lp(a)-C ranged from 0.6-35.0 mg/dL and correlated significantly with Lp(a) molar concentration (r=0.76, p<0.001). The percent Lp(a)-C relative to Lp(a) mass varied from 5.8–57.3% and was not affected by Lp(a) lowering. Baseline LDL-Ccorr was significantly lower than “LDL-C” (mean [SD]) 102.2(31.8) versus 119.2(32.4) mg/dL, p<0.001) and did not correlate with Lp(a)-C. Three commercially-available “direct LDL-C” assays could not differentiate LDL-C from Lp(a)-C.
Conclusions
In conclusion, we developed a novel method to quantitate Lp(a)-C that suggests a broader range of Lp(a)-C relative to mass than previously reported. The use of this method to report a more accurate LDL-C will allow a re-assessment of LDL-Ccorr in clinical medicine.
Presenter of 1 Presentation
O011 - Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements (ID 310)
Abstract
Background and Aims
Current methods for determining “LDL-C” in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. Prior studies suggested Lp(a) mass contains ~30% cholesterol. A high-throughput, sensitive and rapid method to quantitate Lp(a)-C and improve the accuracy of “LDL-C” was developed.
Methods
Lp(a) was isolated on magnetic beads linked to monoclonal antibody LPA4 recognizing apolipoprotein(a) and the cholesterol content measured with standard techniques. This method does not detect cholesterol in plasma samples lacking Lp(a) and is linear up to 747 nM Lp(a). LDL-Ccorr was determined as LDL-C - Lp(a)-C.
Results
Lp(a)-C and LDL-Ccorr were determined in 29 participants from a completed clinical trial of Lp(a) lowering with an antisense oligonucleotide. Baseline Lp(a) ranged from 9.0-822.8 nM, Lp(a)-C ranged from 0.6-35.0 mg/dL and correlated significantly with Lp(a) molar concentration (r=0.76, p<0.001). The percent Lp(a)-C relative to Lp(a) mass varied from 5.8–57.3% and was not affected by Lp(a) lowering. Baseline LDL-Ccorr was significantly lower than “LDL-C” (mean [SD]) 102.2(31.8) versus 119.2(32.4) mg/dL, p<0.001) and did not correlate with Lp(a)-C. Three commercially-available “direct LDL-C” assays could not differentiate LDL-C from Lp(a)-C.
Conclusions
In conclusion, we developed a novel method to quantitate Lp(a)-C that suggests a broader range of Lp(a)-C relative to mass than previously reported. The use of this method to report a more accurate LDL-C will allow a re-assessment of LDL-Ccorr in clinical medicine.